Hereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries
Open Access
- 10 June 2020
- journal article
- research article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 31 (8) , 974-989
Abstract
Background/Methods: At a consensus meeting in August 2018, pediatricians and dermatologists from German‐speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE‐C1‐INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE‐C1‐INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life‐threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This article provides recommendations for developing appropriate treatment strategies in the management of HAE‐C1‐INH in pediatric patients in German‐speaking countries. An overview of available drugs in this age‐group is provided, together with their approval status, and study results obtained in adults and pediatric patients.Results/Conclusion: Currently, plasma‐derived C1 inhibitor concentrates have the broadest approval status and are considered the best available option for on‐demand treatment of HAE‐C1‐INH attacks and for short‐ and long‐term prophylaxis across all pediatric age‐groups in German‐speaking countries. For on‐demand treatment of children aged 2 years and older, recombinant C1‐INH and bradykinin‐receptor antagonist icatibant are alternatives. For long‐term prophylaxis in adolescents, the parenteral kallikrein inhibitor lanadelumab has recently been approved and can be recommended due to proven efficacy and safety.Keywords
Funding Information
- CSL Behring
This publication has 63 references indexed in Scilit:
- Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N‐terminal cleavage site of bradykininAllergy, 2019
- Guideline: Hereditary angioedema due to C1 inhibitor deficiencyAllergo Journal, 2019
- A transcriptomics study of hereditary angioedema attacksJournal of Allergy and Clinical Immunology, 2018
- Angioedema Due to Bradykinin DysregulationThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and updateAllergy, 2018
- Hereditary Angioedema with Normal C1 InhibitorImmunology and Allergy Clinics of North America, 2017
- Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patientsThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiencyAllergy, 2016
- Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in EuropeAllergy, Asthma & Clinical Immunology, 2013
- Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategiesEuropean Journal of Pediatrics, 2012